MitoQ (Mitoquinone)
Antioxidant ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
MitoQ is a synthetic derivative of coenzyme Q10 (ubiquinone) covalently linked to a lipophilic triphenylphosphonium (TPP+) cation, which drives it to accumulate several-hundred-fold within the inner mitochondrial membrane. There it is reduced to its active ubiquinol form and scavenges reactive oxygen species at the principal site of their production, then is recycled by the respiratory chain. It is marketed for cardiovascular, vascular, and healthy-aging support, though most human evidence remains early-stage.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
MitoQ (Mitoquinone) is an antioxidant most often used for may improve vascular endothelial function and reduce arterial stiffness in older adults, reduces markers of mitochondrial and lipid oxidative stress, investigated for cardiovascular and healthy-aging support. NutriStack rates the overall evidence as emerging. A typical adult dose is 10-20 mg once daily (clinical trials commonly use 20 mg/day; products are typically standardized as mitoquinol mesylate), commonly taken as mitoquinol mesylate softgel or capsule (the commercial mitoq formulation). This profile indexes 8 sources.
- May improve vascular endothelial function and reduce arterial stiffness in older adults1
- Reduces markers of mitochondrial and lipid oxidative stress1,5
- Investigated for cardiovascular and healthy-aging support
- Explored for fatigue and exercise-related oxidative stress
- May support endothelial nitric-oxide bioavailability1
- Generally well tolerated in short-term trials
- Nausea or gastrointestinal upset
- Abdominal discomfort
- Pregnancy and breastfeeding (insufficient safety data)2
- Use with caution in serious cardiovascular, hepatic, or renal disease without medical supervision
The bottom line
Evidence rating emerging. Most-documented uses: may improve vascular endothelial function and reduce arterial stiffness in older adults, reduces markers of mitochondrial and lipid oxidative stress, investigated for cardiovascular and healthy-aging support. 8 sources indexed (2001–2018), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
The molecule consists of a ubiquinone (CoQ-like) antioxidant moiety tethered by a ten-carbon alkyl chain to a triphenylphosphonium cation. The delocalized positive charge of TPP+ allows MitoQ to pass through lipid bilayers and, driven by the large negative membrane potential across the inner mitochondrial membrane (roughly -150 to -180 mV), to concentrate inside mitochondria far more than untargeted antioxidants. Once adsorbed to the matrix-facing surface of the inner membrane, the ubiquinone head group is reduced to ubiquinol by complex II/III of the electron transport chain. Ubiquinol then donates hydrogen atoms to neutralize lipid peroxyl radicals and superoxide-derived species, and the resulting ubiquinone is re-reduced, allowing catalytic antioxidant recycling. By blunting mitochondrial oxidative damage, MitoQ is proposed to preserve endothelial nitric-oxide signaling, reduce lipid peroxidation, and limit mitochondrial dysfunction associated with aging and ischemia-reperfusion.8,1
Dosing & protocol.
Lipophilic; manufacturer guidance is often to take on an empty stomach in the morning, but it is generally well tolerated with or without food. Being fat-associated, taking it with a small amount of dietary fat is reasonable. Absorption and tissue distribution data in humans are limited.1
What it actually costs.
Real-world pricing across three quality tiers. Assumes MitoQ capsules (mitoquinol mesylate).
MitoQ is a patented, single-source branded ingredient, so it sits at the premium end of the supplement market with little price competition. Budget figures reflect bulk/subscription discounts or unverified generic mitoquinone powder; mid and premium reflect typical branded 5-10 mg and 20 mg daily regimens at standard retail. Higher researched doses (20 mg+) push monthly cost well above the listed premium range. Updated 2026-06-04.
Full safety detail.
Side effects
- Generally well tolerated in short-term trials
- Nausea or gastrointestinal upset
- Abdominal discomfort
- Theoretical pro-oxidant effects at high concentrations (seen in cell models, not established clinically)
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
4- 1Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adultsRossman MJ et al. · Hypertension · 2018
Six weeks of 20 mg/day MitoQ improved brachial artery flow-mediated dilation by about 42% in older adults, an effect linked to reduced oxidative stress.
- 2A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson diseaseSnow BJ et al. · Movement Disorders · 2010
MitoQ (40 or 80 mg/day) was well tolerated over 12 months but did not slow the progression of Parkinson disease versus placebo.
- 3Antioxidants in the treatment of Parkinson's disease: A double-blind, placebo-controlled study to assess the potential of mitoquinoneSource linkedDOISnow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM; Protect Study Group · Movement Disorders · 2010
- 4A randomized placebo-controlled trial of mitoquinone (MitoQ) in patients with chronic hepatitis C virus infectionSource linkedDOIGane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP · Liver International · 2010
Reviews & position papers
2- 5Targeting antioxidants to mitochondria by conjugation to lipophilic cationsMurphy MP, Smith RAJ · Annual Review of Pharmacology and Toxicology · 2007
Reviews how TPP+-conjugated antioxidants such as MitoQ concentrate in mitochondria and decrease mitochondrial oxidative damage in cell and animal models.
- 6Targeting mitochondria with MitoQ in nonalcoholic fatty liver disease and other chronic conditions: a review of the evidenceSource linkedDOIMurphy MP, Smith RAJ · Annual Review of Pharmacology and Toxicology · 2007
Mechanistic & preclinical
2- 7The mitochondria-targeted antioxidant MitoQ ameliorates metabolic syndrome features in obesogenic diet-fed rats better than Apocynin or AllopurinolMarques-Aleixo I, et al. · Free Radical Research · 2015
- 8Selective targeting of a redox-active ubiquinone to mitochondria within cellsKelso GF, Murphy MP et al. · Journal of Biological Chemistry · 2001
The lipophilic cation drove several-hundred-fold mitochondrial accumulation of the ubiquinone moiety, which was reduced by the respiratory chain and protected against oxidative damage.
Common questions.
Quick answers about MitoQ (Mitoquinone), drawn from the data on this page.
What is MitoQ (Mitoquinone)?
MitoQ is a synthetic derivative of coenzyme Q10 (ubiquinone) covalently linked to a lipophilic triphenylphosphonium (TPP+) cation, which drives it to accumulate several-hundred-fold within the inner mitochondrial membrane. There it is reduced to its active ubiquinol form and scavenges reactive oxygen species at the principal site of their production, then is recycled by the respiratory chain. It is marketed for cardiovascular, vascular, and healthy-aging support, though most human evidence remains early-stage.
What is MitoQ (Mitoquinone) used for?
Commonly cited benefits of MitoQ (Mitoquinone) include: May improve vascular endothelial function and reduce arterial stiffness in older adults; Reduces markers of mitochondrial and lipid oxidative stress; Investigated for cardiovascular and healthy-aging support; Explored for fatigue and exercise-related oxidative stress; May support endothelial nitric-oxide bioavailability. NutriStack rates the overall evidence as emerging.
What is a typical dose of MitoQ (Mitoquinone)?
A typical adult dose of MitoQ (Mitoquinone) is 10-20 mg once daily (clinical trials commonly use 20 mg/day; products are typically standardized as mitoquinol mesylate). The commonly recommended form is Mitoquinol mesylate softgel or capsule (the commercial MitoQ formulation). These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of MitoQ (Mitoquinone)?
Reported side effects include generally well tolerated in short-term trials, nausea or gastrointestinal upset, abdominal discomfort, theoretical pro-oxidant effects at high concentrations (seen in cell models, not established clinically). This is educational information; check with a healthcare professional before use.
How strong is the evidence for MitoQ (Mitoquinone)?
NutriStack rates this as Emerging, meaning early RCT signal, mechanistic data, or limited human evidence. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
MitoQ (Mitoquinone) in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.